Koi Peptides Launches BPC-157 and TB-500 Research Blend with Per-Lot Certificate of Analysis

Koi Peptides (Koi Research Labs LLC) has released a lyophilized, research-use-only blend combining BPC-157 and TB-500 under the catalog designation Wolverine Peptide Stack, with each lot released against a per-batch Certificate of Analysis. For QA directors and laboratory procurement leads, the documentation structure is the operative detail: every vial is traceable to a specific analytical record covering component identity, purity characterization, and release criteria.

The product is positioned strictly as an analytical reference blend for in vitro and controlled laboratory environments. Koi Peptides is explicit that it carries no therapeutic claim and is not offered as a consumer wellness preparation or clinical protocol. The company states the catalog name acknowledges informal online usage of the term "Wolverine stack" as a shorthand for BPC-157 plus TB-500 combinations, while reframing it within a documentation-led, lot-linked format.

On the analytical side, each component is characterized individually. BPC-157, a synthetic pentadecapeptide of fifteen amino acids, is confirmed by peptide sequence and calculated molecular weight. TB-500, a synthetic peptide derived from a fragment of thymosin beta-4, is verified by its own sequence and molecular weight via mass spectrometry. Purity for each component is characterized using reversed-phase high-performance liquid chromatography (HPLC) prior to lot release.

For research facilities sourcing reference peptides, the per-lot Certificate of Analysis approach directly supports material traceability requirements. Linking each vial to a discrete analytical record reduces ambiguity around identity confirmation and purity thresholds, which is a recurring gap when laboratories source peptide materials from suppliers operating without standardized release documentation.

The Wolverine Peptide Stack is supplied as a single lyophilized vial containing both components, intended for handling by qualified research professionals in controlled facilities only. Koi Peptides has not published quantitative purity thresholds or specification limits in the available release materials, a detail procurement and QA teams will need to verify directly against the Certificate of Analysis before integrating the material into any formal research protocol.

Source: Koi Research Labs LLC via GlobeNewswire, June 16, 2026.